These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 37659346)

  • 1. Abbreviated venetoclax with decitabine or azacitidine in acute myeloid leukemia.
    Bouligny IM; Murray G; Ho T; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
    Leuk Res; 2023 Nov; 134():107370. PubMed ID: 37659346
    [No Abstract]   [Full Text] [Related]  

  • 2. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Very long-term efficacy of venetoclax combined with hypomethylating agents in two AML elderly: is it the time for treatment discontinuation strategies?
    Niscola P; Gianfelici V; Giovannini M; Piccioni D; Mazzone C; Fabritiis P
    Ann Hematol; 2024 May; 103(5):1787-1788. PubMed ID: 38459155
    [No Abstract]   [Full Text] [Related]  

  • 4. Toward an improved understanding of hypomethylating agent and venetoclax therapies.
    DiNardo CD
    Am J Hematol; 2024 Feb; 99(2):152-154. PubMed ID: 38102772
    [No Abstract]   [Full Text] [Related]  

  • 5. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
    Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
    Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fully oral regimen with decitabine and cedazuridine plus venetoclax: a new step forward for older or unfit patients with acute myeloid leukaemia.
    Candoni A
    Lancet Haematol; 2024 Apr; 11(4):e245-e246. PubMed ID: 38452789
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination of Venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia: A case series from a single center.
    Secilmis S; Sinan Dal M; Kizil Cakar M; Merdin A; Ahu Baysal N; Altuntas F
    J BUON; 2021; 26(5):2026-2032. PubMed ID: 34761613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An evaluation of venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine as therapy for acute myeloid leukemia.
    Othman TA; Tenold ME; Moskoff BN; Azenkot T; Jonas BA
    Expert Rev Hematol; 2021 May; 14(5):407-417. PubMed ID: 34076549
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen.
    Ohmoto A; Fuji S
    Expert Rev Hematol; 2023; 16(10):761-771. PubMed ID: 37670667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypomethylating agents in combination with venetoclax for acute myeloid leukemia: Update on clinical trial data and practical considerations for use.
    Mei M; Aldoss I; Marcucci G; Pullarkat V
    Am J Hematol; 2019 Mar; 94(3):358-362. PubMed ID: 30499168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCL-2 inhibition in AML: an unexpected bonus?
    Konopleva M; Letai A
    Blood; 2018 Sep; 132(10):1007-1012. PubMed ID: 30037885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic impact of conventional cytogenetics in acute myeloid leukemia treated with venetoclax and decitabine.
    Venugopal S; Maiti A; DiNardo CD; Qiao W; Ning J; Loghavi S; Daver NG; Kadia TM; Rausch CR; Alvarado Y; Ohanian M; Sasaki K; Short NJ; Takahashi K; Yilmaz M; Ravandi F; Kantarjian HM; Konopleva MY
    Leuk Lymphoma; 2021 Dec; 62(14):3501-3505. PubMed ID: 34474640
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of venetoclax and ivosidenib/enasidenib for unfit newly diagnosed patients with acute myeloid leukemia and
    Wang L; Song J; Xiao X; Li D; Liu T; He X
    J Chemother; 2024 May; 36(3):202-207. PubMed ID: 37599456
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.
    DiNardo CD; Maiti A; Rausch CR; Pemmaraju N; Naqvi K; Daver NG; Kadia TM; Borthakur G; Ohanian M; Alvarado Y; Issa GC; Montalban-Bravo G; Short NJ; Yilmaz M; Bose P; Jabbour EJ; Takahashi K; Burger JA; Garcia-Manero G; Jain N; Kornblau SM; Thompson PA; Estrov Z; Masarova L; Sasaki K; Verstovsek S; Ferrajoli A; Weirda WG; Wang SA; Konoplev S; Chen Z; Pierce SA; Ning J; Qiao W; Ravandi F; Andreeff M; Welch JS; Kantarjian HM; Konopleva MY
    Lancet Haematol; 2020 Oct; 7(10):e724-e736. PubMed ID: 32896301
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax.
    Aribi A; Salhotra A; Ball B; Stein A; Marcucci G; Pullarkat V
    Leuk Lymphoma; 2023 Apr; 64(4):897-899. PubMed ID: 36850055
    [No Abstract]   [Full Text] [Related]  

  • 16. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia.
    DiNardo CD; Pratz K; Pullarkat V; Jonas BA; Arellano M; Becker PS; Frankfurt O; Konopleva M; Wei AH; Kantarjian HM; Xu T; Hong WJ; Chyla B; Potluri J; Pollyea DA; Letai A
    Blood; 2019 Jan; 133(1):7-17. PubMed ID: 30361262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venetoclax with decitabine or azacitidine in relapsed or refractory acute myeloid leukemia.
    Bouligny IM; Murray G; Doyel M; Patel T; Boron J; Tran V; Gor J; Hang Y; Alnimer Y; Ho T; Zacholski K; Venn C; Wages NA; Grant S; Maher KR
    Med Oncol; 2024 Feb; 41(3):80. PubMed ID: 38396145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of therapy-related acute myeloid leukemia and underlying multiple myeloma with decitabine/venetoclax and daratumumab.
    Shoumariyeh K; Jung J; Rassner M; Dold SM; Riebl V; Pantic M; Herget G; Marks R; Lübbert M; Wäsch R; Engelhardt M
    Ann Hematol; 2021 Jun; 100(6):1637-1640. PubMed ID: 33712868
    [No Abstract]   [Full Text] [Related]  

  • 19. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
    Gangat N; Guglielmelli P; Szuber N; Begna KH; Patnaik MM; Litzow MR; Al-Kali A; Foran JM; Palmer JM; Alkhateeb H; Elliott MA; Hanson CA; Pardanani A; Mannelli F; Vannucchi AM; Tefferi A
    Am J Hematol; 2021 Jul; 96(7):781-789. PubMed ID: 33844862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Venetoclax-based chemotherapy in acute and chronic myeloid neoplasms: literature survey and practice points.
    Gangat N; Tefferi A
    Blood Cancer J; 2020 Nov; 10(11):122. PubMed ID: 33230098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.